The Ryanodine Receptor in Cardiac Physiology and Disease

Alexander Kushnir, Andrew R. Marks

Research output: Chapter in Book/Report/Conference proceedingChapter

99 Scopus citations


According to the American Heart Association it is estimated that the United States will spend close to $39 billion in 2010 to treat over five million Americans suffering from heart failure. Patients with heart failure suffer from dyspnea and decreased exercised tolerance and are at increased risk for fatal ventricular arrhythmias. Food and Drug Administration -approved pharmacologic therapies for heart failure include diuretics, inhibitors of the renin-angiotensin system, and Β-adrenergic receptor antagonists. Over the past 20 years advances in the field of ryanodine receptor (RyR2)/calcium release channel research have greatly advanced our understanding of cardiac physiology and the pathogenesis of heart failure and arrhythmias. Here we review the key observations, controversies, and discoveries that have led to the development of novel compounds targeting the RyR2/calcium release channel for treating heart failure and for preventing lethal arrhythmias.

Original languageEnglish (US)
Title of host publicationAdvances in Pharmacology
PublisherAcademic Press Inc.
Number of pages30
StatePublished - 2010
Externally publishedYes

Publication series

NameAdvances in Pharmacology
ISSN (Print)1054-3589


  • Excitation-contraction coupling
  • Heart failure
  • Ryanodine receptor

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The Ryanodine Receptor in Cardiac Physiology and Disease'. Together they form a unique fingerprint.

Cite this